Rubius Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2017 to Q4 2022

Taxonomy & unit: us-gaap: USD
Description: Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary: Rubius Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2017 to Q4 2022.
Rubius Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending December 31, 2022 was -$1.32M, a 114% decline year-over-year.
Rubius Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending December 31, 2022 was $15.8M, a 55.7% decline year-over-year.
Rubius Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $15.8M, a 55.7% decline from 2021.
Rubius Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $35.6M, a 5.78% increase from 2020.
Rubius Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2020 was $33.7M, a 18.4% decline from 2019.

Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)

Share-based Payment Arrangement, Expense, Quarterly (USD)

Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q4 2022	$15.8M	-$1.32M	-$10.5M	-114%	Oct 1, 2022	Dec 31, 2022	10-K	2023-02-27
Q3 2022	$26.3M	$3.8M	-$4.39M	-53.6%	Jul 1, 2022	Sep 30, 2022	10-Q	2022-11-09
Q2 2022	$30.7M	$5.04M	-$4.56M	-47.5%	Apr 1, 2022	Jun 30, 2022	10-Q	2022-08-09
Q1 2022	$35.2M	$8.26M	-$382K	-4.42%	Jan 1, 2022	Mar 31, 2022	10-Q	2022-05-10
Q4 2021	$35.6M	$9.18M	+$242K	+2.71%	Oct 1, 2021	Dec 31, 2021	10-K	2023-02-27
Q3 2021	$35.4M	$8.19M	+$204K	+2.56%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-09
Q2 2021	$35.2M	$9.6M	+$1.35M	+16.3%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-09
Q1 2021	$33.8M	$8.64M	+$154K	+1.81%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-10
Q4 2020	$33.7M	$8.94M	-$1.89M	-17.5%	Oct 1, 2020	Dec 31, 2020	10-K	2023-02-27
Q3 2020	$35.6M	$7.99M	-$2.37M	-22.9%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-08
Q2 2020	$37.9M	$8.25M	-$2.35M	-22.2%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-09
Q1 2020	$40.3M	$8.49M	-$990K	-10.4%	Jan 1, 2020	Mar 31, 2020	10-Q/A	2021-08-20
Q4 2019	$41.3M	$10.8M	+$1.71M	+18.7%	Oct 1, 2019	Dec 31, 2019	10-K	2022-02-25
Q3 2019	$39.6M	$10.4M	+$471K	+4.76%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-09
Q2 2019	$39.1M	$10.6M	+$4.7M	+79.7%	Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-10
Q1 2019	$34.4M	$9.48M	+$6.87M	+263%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-11
Q4 2018	$27.5M	$9.13M			Oct 1, 2018	Dec 31, 2018	10-K	2021-02-23
Q3 2018		$9.89M	+$5.75M	+139%	Jul 1, 2018	Sep 30, 2018	10-Q	2019-11-14
Q2 2018		$5.9M			Apr 1, 2018	Jun 30, 2018	10-Q	2019-08-13
Q1 2018		$2.61M			Jan 1, 2018	Mar 31, 2018	10-Q	2019-05-15
Q3 2017		$4.14M			Jul 1, 2017	Sep 30, 2017	10-Q	2018-11-13

* An asterisk sign (*) next to the value indicates that the value is likely invalid.